Amarin Corp Plc (AMRN)

[yellow_bluff]

For JL and his scleroderma research:

Amazing device and approach that CYTX has to using regenerative cells; multiple applications for the device; but a bear to get out into the market.

Cytori Therapeutics posts preliminary data from Scleroderma study
Friday, September 20, 2013 02:05:12 PM (GMT)


CYTX posted preliminary results on its website:
CYTX announces positive early data from a study evaluating Cytori’s cell therapy as a potential treatment for scleroderma, a rare autoimmune disorder.
The results will be presented today by the principal investigator of the study at H?pital de la Conception, AP-HM Marseille, France, at the 3rd Annual Cell Society Meeting.
As part of the study, 12 patients received injection of Cytori’s cell therapy into their fingers. The primary endpoints are safety, and the improvement in function of the hands, as measured by the Cochin hand functional scale at six months. At two month follow-up, the following outcomes were observed:
Primary
No reports of infection, ischemic complications or serious adverse events;
Significant improvement in the Cochin hand function disability scale (48.5±10.8 to 25.5±16.5, p<0.001)
Secondary
Significant improvement in hand pain, as measured by the visual analog pain scale (from 59.4±17.2 to 21.6±17.5, p<0.001);
Significant improvement in scleroderma health assessment questionnaire score (p<0.001);
Significant improvement in Raynaud’s Severity Score (p<0.001).


Industries: Medical Equipment & Supplies
Primary Company: CYTX-US
Related Identifiers: CYTX-US
Reference Links: ir.cytori.com
Related Stories:
Cytori Therapeutics announces initiation of cell therapy trial in France